

Melanoma Guideline – Review Questions

Melanoma: Review Questions

- What are the specific information needs of people with melanoma and their carers at different milestones/points in the patient pathway?
- What are the specific support needs of people with melanoma and their carers at different milestones/points in the patient pathway?
- What are the most effective ways of meeting the patients information needs?
- What are the most effective ways of meeting the patients support needs?
- To what extent can the diagnostic accuracy of, history-taking and visual examination for the clinical identification of melanoma be improved by dermoscopy or/and new visualisation techniques?
- Is photography an effective method of detecting progression of pigmented lesions, including dermoscopy pictures?
- What is the best approach to resolving clinico-pathological diagnostic uncertainty for borderline or spitzoid melanocytic lesions?
- What is the most appropriate tumour sample (primary or secondary) on which to carry out genetic testing to identify people who might benefit from targeted therapies?
- What is the role of genetic testing of the tumour at diagnosis for a person with early stage [I-III] melanoma?
- What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IA melanoma?
- What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IB-IIIC melanoma?
- What is the most effective method of accurately staging melanoma in patients with clinicopathological stage III melanoma?
- What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IV melanoma?
- What is the most effective surgical treatment for stage 0-II melanoma to achieve clear margins and improved patient outcomes?
- How effective is imiquimod in the treatment of stage 0 melanoma and skin metastases?
- What is the most effective surgical treatment for stage III melanoma?
- What is the effectiveness of adjuvant radiotherapy to the resected lymph node basin for stage III melanoma in people who have undergone curative resection?
- What is the most effective treatment for in transit melanoma metastases (for example, surgery, isolated limb infusion, isolated limb perfusion, palliative radiotherapy, cryotherapy, electro-chemotherapy or the laser)?
- How effective is surgery, ablative treatments or stereotactic radiotherapy for people with stage IV melanoma with oligometastatic disease?
- What is the effectiveness of local treatment using surgery or radiotherapy compared with systemic drug therapy or supportive care in the management of brain metastases in people with stage IV melanoma?
- What is the effectiveness of systemic anticancer therapy compared with supportive care in the treatment (first and second line) of patients with stage IV metastatic melanoma?
- In asymptomatic patients who have undergone treatment with curative intent for melanoma, what is the optimal method, frequency and duration of follow-up?
- In patients with melanoma who are undergoing body imaging as part of follow-up and who have no neurological signs or symptoms, should brain imaging be included?
- Where imaging is indicated, is CT or MRI the most appropriate method of imaging for brain metastasis as part of follow-up for asymptomatic patients?
- How should sub-optimal vitamin D levels be managed in people with melanoma (including supplements and monitoring)?

Melanoma Guideline – Review Questions

- What is the most effective approach to the management of risks to patients associated with concurrent drug therapies used to treat other conditions, which may affect the prognosis from melanoma (for example, immunosuppressants, levodopa, metformin, HRT, COCP)?